Omega-3 Petition Outcome Will Reveal FDA Biomarker Stance
This article was originally published in The Tan Sheet
Executive Summary
A citizen petition for omega-3 cardiovascular health claims is the first since the Institute of Medicine in 2010 recommended a framework to assess biomarkers for supplement health claims. The petition also will show whether FDA changed its thinking about supplement claims, says former FDA dietary supplement programs head Bill Frankos.
You may also be interested in...
IOM Proposal Could Open Door For Biomarkers In Supplement Research
An Institute of Medicine report recommending a framework for assessing biomarkers for food and supplement health claims could help the supplement industry because it "will set the stage for being able to validate more biomarkers," said Andrew Shao, senior VP of scientific and regulatory affairs with the Council for Responsible Nutrition
FDA Identifies "Fatal Flaws" That Block Approval Of Health Claims
FDA likely will refuse new health claims applications if petitioners fail to provide relevant studies in healthy humans that evaluate the relationship between the substance and the disease, an agency official says
US Health And Wellness People News: CHPA, Bayer, Viatris, Qnovia, Powerade
Sanofi consumer health scientific affairs lead moves to CHPA; change in Bayer’s US consumer health marketing helm; Viatris CCO moves from same post at Moderna; Qnovia expands scientific advisory board; and Powerade powers Girls Inc. scholarships, programs.